Thomas Jefferson University

The pace of IPOs in 2022 is far below the record-breaking number of first-time offerings in 2021, with the last initial public offering in the US by a biopharmaceutical company completed by Acrivon T

BridgeBio Pharma, Inc. employs a business model of acquiring rights to or partnering with academic and institutional research in monogenic diseases and genetic cancer indications, often forming singl

Zydus Cadila , one of the COVID-19 vaccine hopefuls, is going all out in a fight against the disease, taking to seven the total number of prophylactics or therapies it is currently developing or explo

Bharat Biotech has claimed “at least 60%” efficacy for its whole virion, inactivated COVID-19 vaccine candidate Covaxin and is preparing for a launch during the fiscal second quarter ending 30 Septem